Protalix Biotherapeutics Inc (NYSE American:PLX)

3.46
Delayed Data
As of 3:59pm ET
 -0.07 / -1.98%
Today’s Change
1.85
Today|||52-Week Range
4.87
+5.49%
Year-to-Date
SECTOR
Health Services
INDUSTRY
Services to the Health Industry
MARKET CAP
$123.3M

Company Description

Protalix Biotherapeutics, Inc. engages in the development, production, and commercialization of recombinant therapeutic proteins based on plant cell based expression system. Its products include Alidornase alfa and OPRX-106. The company was by Yoseph Shaaltiel in 1993 and is headquartered in Karmiel, Israel.

Contact Information

Protalix Biotherapeutics, Inc.
2 Snunit Street
Karmiel Hazafon 2161401
P:(724) 902-8100
Investor Relations:

Employees

Shareholders

Mutual fund holders4.87%
Individual stakeholders2.98%
Other institutional14.42%

Top Executives

Dror BashanPresident, Chief Executive Officer & Director
Yaron NaosSenior Vice President-Operations
Eyal RubinChief Financial Officer, Secretary & Senior VP
Yael HayonVice President-Research & Development
Raul ChertkoffVice President-Medical Affairs